Topic: glioblastoma multiforme (GBM)
After steering Spark's Luxturna through FDA approval and launch, COO John Furey is heading Imvax, which is developing a brain cancer vaccine.
A Cedars-Sinai team used a polymer scaffold to deliver two types of immune checkpoint inhibitors in mouse models of glioblastoma.
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.
The deal will give Merck control of an experimental oral HIF-2α inhibitor that may challenge Keytruda for the metastatic renal cell carcinoma market.
AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.
Immune molecules from sea lampreys could inspire new treatments for brain tumors, trauma and neurodegenerative diseases.
The week’s biotech news included new technology for detecting off-target effects of CRISPR and gene variants that shield against obesity.
TwoXAR's drug discovery partnership with South Korea’s 1ST Biotherapeutics is the company's third.
A phase 3 study from imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in glioma diagnoses.